Contact usWorldwide
HomeAbout RosettaOur ScienceCareers
 

2001 Publications
 Clustering of Hepatotoxins Based on Mechanism of Toxicity Using Gene Expression Profiles
Toxicology and Applied Pharmacology 175, 28–42 (2001).
Opens New Window 

(Note: Current Rosetta Inpharmatics employees are shown in boldface type.)

Jeffrey F. Waring, Robert A. Jolly, Rita Ciurlionis, Pek Yee Lum, Jens T. Praestgaard, David C. Morfitt, Bruno Buratto, Chris Roberts, Eric Schadt, and Roger G. Ulrich

Abstract

Microarray technology, which allows one to quantitate the expression of thousands of genes simultaneously, has begun to have a major impact on many different areas of drug discovery and development. The question remains of whether microarray analysis and gene expression signature profiles can be applied to the field of toxicology. To date, there are very few published studies showing the use of microarrays in toxicology and important questions remain regarding the predictability and accuracy of applying gene expression profiles to toxicology. To begin to address these questions, we have treated rats with 15 different known hepato-toxins, including allyl alcohol, amiodarone, Aroclor 1254, arsenic, carbamazepine, carbon tetrachloride, diethylnitrosamine, dimeth-ylformamide, diquat, etoposide, indomethacin, methapyrilene, methotrexate, monocrotaline, and 3-methylcholanthrene. These agents cause a variety of hepatocellular injuries including necrosis, DNA damage, cirrhosis, hypertrophy, and hepatic carcinoma.

Gene expression analysis was done on RNA from the livers of treated rats and was compared against vehicle-treated controls. The gene expression results were clustered and compared to the histopathology findings and clinical chemistry values. Our results show strong correlation between the histopathology, clinical chem-istry, and gene expression profiles induced by the agents. In addition, genes were identified whose regulation correlated strongly with effects on clinical chemistry parameters. Overall, the results suggest that microarray assays may prove to be a highly sensitive technique for safety screening of drug candidates and for the classification of environmental toxins.

Downloading Data

The data and additional information supporting this paper are currently available for  download in PDF format (1.3MB). (opens new window)

Opens New Window


Printer Friendly Page
 

About Rosetta

Rosetta Inpharmatics was founded in 1996 to design and implement DNA microarray gene expression technologies...Learn more
 
Site Map Privacy Policy - Opens New Window Trademarks - Opens New Window Terms of Use - Opens New Window Copyright © 2004-2007 Rosetta Inpharmatics LLC. - Opens New Window Merck & Co., Inc. (USA) - Opens New Window